The honest bottom line comes first: there is no officially established, validated, or regulatory-approved dose for TB-500, and every figure attached to it traces back to informal user communities and supplier marketing rather than completed human clinical trials. TB-500 is a synthetic peptide related to a fragment of thymosin beta-4, sold and labeled as a research chemical not intended for human use, so the numbers around it have never passed through the dose-finding studies that establish a safe range for an approved drug. The anecdotal record describes a lyophilized powder reconstituted with bacteriostatic water and given by subcutaneous or intramuscular injection on a loading-and-maintenance shape, with milligram figures that vary widely because none rest on controlled study.
No validated clinical dose for TB-500 exists, and every milligram figure that circulates originates in user communities and supplier marketing rather than from completed human dose-finding trials.
An established dose is the output of a specific process, not an opinion: dose-finding trials in humans identify a range that balances effect against toxicity, and a regulatory authority reviews that evidence before authorizing a labeled dose for a defined use. TB-500 has never traveled that path. It is labeled as a research chemical not approved for human use, which means the completed, controlled human trials that would generate a validated dose have not happened.
An officially established dose exists only after completed human dose-finding trials and regulatory authorization, a pathway TB-500 has never entered, which is why no authoritative number exists and only unverified supplier and user claims remain.
The figures for TB-500 live almost entirely in two overlapping places: posts in informal user communities and the marketing copy on supplier product pages. The same number repeated across multiple pages often reflects copying between sources rather than independent confirmation, which can give a false sense that a figure is settled when it is only widely echoed.
The dosage figures circulating for TB-500 originate entirely in informal communities and supplier marketing, and a number's frequent repetition reflects copying between sources rather than any controlled human evidence that would make it a validated dose.
In the informal material, TB-500 is described as given by injection, most often subcutaneously into the fatty layer just under the skin or intramuscularly into a muscle. Oral administration is generally not described as workable, because a peptide of this kind would be expected to break down in the digestive tract if swallowed. The descriptions stop at noting both routes; they do not converge on validated guidance about which is preferable.
| Route | Subcutaneous | Intramuscular |
|---|---|---|
| Site described | Fatty layer just under the skin | Into a muscle |
| Basis for use | Anecdotal reports only | Anecdotal reports only |
| Comparative evidence | No controlled study favoring either | No controlled study favoring either |
TB-500 is described in informal sources as administered by subcutaneous or intramuscular injection, with oral use not considered workable because the peptide would break down in the digestive tract, and no controlled study establishes either injection route as preferable.
TB-500 is typically supplied as a lyophilized powder, freeze-dried into a stable solid because the peptide keeps better dry than in solution. The handling steps that appear in anecdotal sources describe reconstitution with bacteriostatic water, which is sterile water carrying a small amount of benzyl alcohol meant to inhibit bacterial growth across repeated draws from the same vial. This is a description of what circulates, not a validated preparation procedure, and it carries genuine sterility and contamination risk because the identity and purity of a research-chemical powder are not assured.
Anecdotal sources describe reconstituting lyophilized TB-500 with bacteriostatic water, where the diluent volume relative to the powder sets the final concentration, but this is an informal handling description carrying real sterility and purity risk, not a validated preparation procedure.
The protocol shape that recurs in informal TB-500 discussion is a two-phase loading-and-maintenance structure, a framing borrowed from other contexts rather than derived from study. It appears across many reports partly because sources copy the pattern from one another, which should not be mistaken for scientific support.
The anecdotal loading-and-maintenance structure for TB-500 describes a higher-frequency early phase followed by reduced ongoing dosing, but it rests on no completed human trial and is a borrowed convention rather than a validated regimen.
When users explain how they landed on a particular figure, they point to factors such as body weight, a stated goal, prior experience, or simply what a supplier or another user suggested. These rationales can sound tailored, but the appearance of customization is guesswork layered on guesswork, because no standardized relationship between any factor and a safe outcome has been established for TB-500 in controlled human study. Individual variation actually cuts against borrowing community figures rather than supporting it.
The factors people cite to justify a TB-500 figure, including body weight, goal, and prior experience, rest on no established relationship to a safe outcome and do not convert an unvalidated number into a sound one.
The research-chemical or not-for-human-use label is not a formality; it shapes everything about how TB-500 is handled and discussed. It signifies that the product was never authorized for human consumption, so it sits outside the manufacturing oversight and quality assurance that govern approved medicines, and there is no guarantee a given vial contains what it claims at the stated amount and free of contaminants.
The research-chemical label means TB-500 was never authorized for human use and falls outside manufacturing oversight, so its purity and identity are unverified and every dosing figure attached to it should be discounted heavily.
The safety concerns around TB-500 stack on top of one another, and the dosing question is only one layer. Acting on a figure that never went through dose-finding study means there is no established safety margin at all, so there is no way to know what amount might cause harm, and every layer above that compounds the uncertainty.
Unvalidated TB-500 dosing carries no established safety margin, and self-administration layers on injection hazards, unverified product purity, absent clinical monitoring, and unknown long-term human effects.
A licensed clinician brings exactly what informal sources cannot: the ability to assess a specific person rather than recite a generic figure. Community and marketing sources are structurally unreliable here because they lack individual context, supplier sources carry a commercial incentive to sell, and user reports describe one person's experience with an unverified product rather than validated guidance.
Questions about TB-500 belong with a licensed clinician because the absence of a validated dose, the commercial incentive behind supplier sources, and the lack of individual context in community reports make professional, individualized assessment the safer default.
Educational use only. This article describes what the published scientific and clinical literature reports about TB-500. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
